We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biweekly Paclitaxel and Gemcitabine for Patients with Advanced Urothelial Cancer Ineligible for Cisplatin-Based Regimen.
- Authors
Takahashi, Takeshi; Higashi, Shin; Nishiyama, Hiroyuki; Segawa, Takeshiko; Nakamura, Eijiro; Kinoshita, Hidefumi; Itoh, Noriyuki; Yamamoto, Shingo; Kamoto, Toshiyuki; Habuchi, Tomonori; Ogawa, Osamu
- Abstract
Background: To avoid cisplatin-related gastrointestinal, renal and other toxicity while maintaining efficacy in the palliative setting or second line chemotherapeutic regimen for cisplatin-resistant urothelial cancer, chemotherapeutic regimens have been investigated that do not include cisplatin. The current study was designed to evaluate efficacy, clinical feasibility and safety of gemcitabine and paclitaxel (GP) regimen in patients with metastatic urothelial cancer who were ineligible for standard cisplatin-based combination chemotherapy.
- Publication
Japanese Journal of Clinical Oncology, 2006, Vol 36, Issue 2, p104
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyi220